Alterity Therapeutics confirms FDA Phase 3 design for ATH434 in MSA
Alterity Therapeutics has confirmed that the US Food and Drug Administration has agreed with the proposed Phase 3 design for ATH434 in Multiple System Atrophy (MSA), following receipt of End-of-Phase 2 meeting minutes. The dual-listed company, which trades on the ASX and NASDAQ, said the FDA's alignment on study population, treatment regimen, and primary endpoint clears the path for a pivotal registrational trial and a potential New Drug Application.
The Phase 3 trial is expected to enrol approximately 200 patients, randomised 1:1 to ATH434 50 mg or placebo twice daily over 12 months. The primary endpoint is the 11-item Unified Multiple System Atrophy Rating Scale Part I, a functional measure capturing activities of daily living. The FDA indicated that a single pivotal trial, supported by confirmatory evidence from the completed Phase 2 study, could provide a sufficient basis for approval. Alterity said it has begun operational start-up activities including protocol finalisation, vendor selection, site identification, and manufacture of the first registration batch of ATH434.
Intellectual property and clinical evidence
Alongside the regulatory milestone, Alterity secured a new US composition of matter patent from the USPTO covering a crystalline mesylate salt form of ATH434, the same form used in Phase 2 and planned for Phase 3. The patent expires in 2045 and, upon approval, is expected to be listed in the FDA's Orange Book. Alterity also holds Orphan Drug Designation in both the US and the EU, providing market exclusivity on top of the newly extended patent term. The company noted the patent supports future development in Parkinson's disease, where iron dysregulation is also implicated.
On the clinical evidence front, Alterity presented additional Phase 2 analyses at the International Congress of Parkinson's Disease and Movement Disorders in October 2026. Using statistical methods planned for Phase 3, the post-hoc analysis showed ATH434 50 mg slowed functional decline by approximately 52% versus placebo on the 11-item UMSARS Part I at week 52. Separately, a peer-reviewed publication in Clinical Autonomic Research from the bioMUSE Natural History Study linked phosphorylated alpha-synuclein deposition in skin biopsies to autonomic dysfunction in early MSA, supporting skin biopsy as a monitoring tool in future trials.
Financial position and partnering
Alterity reported a cash balance of A$41.3 million as at 30 September 2026, bolstered by an A$3.98 million Australian R&D Tax Incentive refund and approximately A$5.5 million net proceeds from the exercise of listed ATHO options. Operating cash outflows for the quarter were modest at A$1.34 million. The company acknowledged it is continuing to evaluate strategic funding and partnering alternatives, including discussions with a number of pharmaceutical companies, and has engaged external advisers to run a structured process.
MSA is a rare, rapidly progressive neurodegenerative disease for which no approved disease-modifying therapy currently exists. The small patient population and high unmet need make Orphan Drug Designation commercially meaningful, but Phase 3 execution risk remains substantial: the condition is difficult to diagnose early, recruitment timelines for rare neurological trials are typically extended, and Alterity will need to secure additional capital or a development partner to fund a 200-patient, 12-month pivotal study through to readout. The company's cash position provides near-term runway, but investors will focus closely on the outcome of the partnering process as the primary determinant of whether Phase 3 can be initiated on a commercially viable timeline.
Chief executive David Stamler said the quarter represented "meaningful progress," pointing to the FDA alignment and the strengthened intellectual property position as complementary pillars supporting ATH434's long-term value proposition.